Nash Clinical Trials

Dive into the latest updates and breakthroughs from clinical trials targeting Non-Alcoholic Steatohepatitis (NASH). Understand how these trials are shaping the future of NASH treatment

Exploring Emerging Anti-Inflammatory and -Fibrotic Therapeutic Targets for NASH

Authors: Tacke F, Puengel T, Loomba R et al.
Published in Journal of Hepatology (August 2023)
Non-alcoholic fatty liver disease (NAFLD) can be categorised into two disease sub-classifications: non-alcoholic fatty liver (NAFL), its non-progressive subtype, and non-alcoholic steatohepatitis (NASH), its progressive form.
Read MoreExploring Emerging Anti-Inflammatory and -Fibrotic Therapeutic Targets for NASH

Exploring the Potential Link Between COVID-19 and the Surge in Pediatric NAFLD

Authors: Slusher AL, Hu P, Samuels S et al.
Published in Pediatric Obesity (December 2022)
Non-alcoholic fatty liver disease (NAFLD), the most common liver disease in children, has seen a consistent rise in prevalence in recent years due to its direct link with obesity and type 2 diabetes (T2D).
Read MoreExploring the Potential Link Between COVID-19 and the Surge in Pediatric NAFLD

“Refining Strategies And Redefining Success”: Lessons Learned From Failed Nash Trials

Authors: Francque SM, Noureddin M, Krag A
Published in Clinical Gastroenterology and Hepatology (August 2023)
Despite ample preclinical evidence of numerous compounds’ efficacy and over 15 years of clinical trials, no pharmacotherapy has yet been approved to treat non-alcoholic steatohepatitis (NASH)
Read More“Refining Strategies And Redefining Success”: Lessons Learned From Failed Nash Trials

Understanding Nash: Symptoms, Detection, And Treatment

Authors: Basu M, Noureddin M, Clark JM
Published in Mayo Clinic Proceedings (September 2022)
Nonalcoholic steatohepatitis (NASH), the progressive form of nonalcoholic fatty liver disease (NAFLD), has seen a consistent rise in prevalence in recent years owing to the global epidemics of obesity and type 2 diabetes (T2D)
Read MoreUnderstanding Nash: Symptoms, Detection, And Treatment

A brief introduction to the most promising pharmacological agents for NASH

Authors: Ratziu V and Tacke F
Published in Journal of Hepatology (July 2023)
The last decade has seen an unprecedented amount of data in the way of therapeutic research for non-alcoholic steatohepatitis (NASH), the progressive form of non-alcoholic fatty liver disease (NAFLD).
Read MoreA brief introduction to the most promising pharmacological agents for NASH

NASH Progression and Clinical Outcomes: Defining Predictive LSM-VCTE Thresholds

Authors: Loomba R, Huang DQ, Sanyal AJ et al.
Published in Gut (March 2023)
In patients with non-alcoholic steatohepatitis (NASH), the risk of liver-related mortality and decompensation is known to increase proportionally with fibrosis stage. Non-invasive tools, including liver stiffness by vibration-controlled transient elastography (LS-VCTE), have been shown to accurately predict fibrosis stage in NASH patients.
Read MoreNASH Progression and Clinical Outcomes: Defining Predictive LSM-VCTE Thresholds

SUBSCRIBE & FOLLOW US

SUBSCRIBE TO OUR MONTHLY NEWSLETTER TO GET THE LATEST UPDATES